Tamara Pringsheim1, Donald Addington2. 1. 1 Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences, University of Calgary, Calgary, Alberta. 2. 2 Department of Psychiatry, University of Calgary, Calgary, Alberta.
Abstract
INTRODUCTION: The aim of the Canadian Schizophrenia Guidelines is to provide evidence-based recommendations for the treatment of schizophrenia and schizophrenia spectrum disorders. The target users are health care professionals. Recommendations are provided as guidance to physicians and patients, with the goal of improving the overall standard of care of individuals with schizophrenia. METHODS: The guidelines were developed using the ADAPTE process, a systematic approach and alternative to de novo guideline development, in which an existing guideline is customised to suit the local context. We assembled a multidisciplinary team of experts, patients, and family carers from across Canada with the goal of involving individuals with diverse areas of expertise and offering different perspectives. RESULTS: We identified 6 guidelines that were suitable for adaptation. Recommendations from each guideline were extracted and, based on content, were reviewed by the relevant working group. Each working group examined the evidence from which the recommendation was derived and the acceptability and applicability of the recommendation to the Canadian context. Working groups also made decisions on modifications to recommendations when language or terms differed between the source guideline and the Canadian context. Each working group presented selected recommendations to the guideline panel at an in-person consensus meeting. Once the consensus process was completed, each working group created a manuscript with the recommendations adapted from the included guidelines, with the rationale for each recommendation. CONCLUSIONS: The process yielded an up-to-date list of evidence-based recommendations that are relevant and applicable in Canada.
INTRODUCTION: The aim of the Canadian Schizophrenia Guidelines is to provide evidence-based recommendations for the treatment of schizophrenia and schizophrenia spectrum disorders. The target users are health care professionals. Recommendations are provided as guidance to physicians and patients, with the goal of improving the overall standard of care of individuals with schizophrenia. METHODS: The guidelines were developed using the ADAPTE process, a systematic approach and alternative to de novo guideline development, in which an existing guideline is customised to suit the local context. We assembled a multidisciplinary team of experts, patients, and family carers from across Canada with the goal of involving individuals with diverse areas of expertise and offering different perspectives. RESULTS: We identified 6 guidelines that were suitable for adaptation. Recommendations from each guideline were extracted and, based on content, were reviewed by the relevant working group. Each working group examined the evidence from which the recommendation was derived and the acceptability and applicability of the recommendation to the Canadian context. Working groups also made decisions on modifications to recommendations when language or terms differed between the source guideline and the Canadian context. Each working group presented selected recommendations to the guideline panel at an in-person consensus meeting. Once the consensus process was completed, each working group created a manuscript with the recommendations adapted from the included guidelines, with the rationale for each recommendation. CONCLUSIONS: The process yielded an up-to-date list of evidence-based recommendations that are relevant and applicable in Canada.
Authors: Melissa C Brouwers; Michelle E Kho; George P Browman; Jako S Burgers; Francoise Cluzeau; Gene Feder; Béatrice Fervers; Ian D Graham; Jeremy Grimshaw; Steven E Hanna; Peter Littlejohns; Julie Makarski; Louise Zitzelsberger Journal: CMAJ Date: 2010-07-05 Impact factor: 8.262
Authors: Melanie Lovell; Tim Luckett; Frances Boyle; John Stubbs; Jane Phillips; Patricia Mary Davidson; Ian Olver; Jutta von Dincklage; Meera Agar Journal: Asia Pac J Clin Oncol Date: 2015-04-14 Impact factor: 2.601
Authors: S J Schmidt; F Schultze-Lutter; B G Schimmelmann; N P Maric; R K R Salokangas; A Riecher-Rössler; M van der Gaag; A Meneghelli; M Nordentoft; M Marshall; A Morrison; A Raballo; J Klosterkötter; S Ruhrmann Journal: Eur Psychiatry Date: 2015-03-03 Impact factor: 5.361
Authors: Paolo Fusar-Poli; Ilaria Bonoldi; Alison R Yung; Stefan Borgwardt; Matthew J Kempton; Lucia Valmaggia; Francesco Barale; Edgardo Caverzasi; Philip McGuire Journal: Arch Gen Psychiatry Date: 2012-03
Authors: Jean Addington; Donald Addington; Sabina Abidi; Thomas Raedler; Gary Remington Journal: Can J Psychiatry Date: 2017-07-21 Impact factor: 4.356
Authors: Tania Lecomte; Sabina Abidi; Iliana Garcia-Ortega; Irfan Mian; Kevin Jackson; Kim Jackson; Ross Norman Journal: Can J Psychiatry Date: 2017-09 Impact factor: 4.356
Authors: Giulia M Giordano; Francesco Brando; Pasquale Pezzella; Maria De Angelis; Armida Mucci; Silvana Galderisi Journal: Front Psychiatry Date: 2022-08-30 Impact factor: 5.435
Authors: Jessica D'Arcey; Joanna Collaton; Nicole Kozloff; Aristotle N Voineskos; Sean A Kidd; George Foussias Journal: JMIR Ment Health Date: 2020-04-02
Authors: Tania Lecomte; Jean Addington; Chris Bowie; Martin Lepage; Stéphane Potvin; Jai Shah; Chris Summerville; Phil Tibbo Journal: Can J Psychiatry Date: 2021-04-19 Impact factor: 4.356